Domiciliary Oxygen Therapy In Interstitial Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$124,608.00
Summary
Interstitial lung diseases (ILD) are chronic lung diseases with significant health impacts, but limited drug treatment options. Although home oxygen treatment (HOT) is commonly used in these patients, its clinical benefits are uncertain with potential risks and significant costs for both patients and the health care system. Very little published information is available on the use of HOT in these patients. These studies aim to improve our knowledge and management of HOT in patients with ILD.
A Randomised Controlled Trial Of Non-invasive Ventilation In Stable, Hypercapnic Chronic Airflow Limitation
Funder
National Health and Medical Research Council
Funding Amount
$331,622.00
Summary
Chronic airflow limitation is a major cause of illness and death in Australia. Long term oxygen therapy is well established as one means of assisting people with chronic lung disease. Survival is still poor particularly when an individual is hypercapnic. Non-invasive ventilation used at night with a mask has been used in chronic hypercapnic respiratory failure from other causes with very good results. This study looks at whether non-invasive mask ventilation improves survival, improves clinical ....Chronic airflow limitation is a major cause of illness and death in Australia. Long term oxygen therapy is well established as one means of assisting people with chronic lung disease. Survival is still poor particularly when an individual is hypercapnic. Non-invasive ventilation used at night with a mask has been used in chronic hypercapnic respiratory failure from other causes with very good results. This study looks at whether non-invasive mask ventilation improves survival, improves clinical outcome measures and reduces health costs in people with chronic airflow limitation. The ventilatory support will be used at night during sleep and will be a bilevel positive airway pressure device. Apart from measuring the cost-benefit of home ventilatory support, this study will examine the relationship between the time of commencement of home ventilatory support and outcomes. In addition the relationships between daytime awake PaCO2, lung function, and body mass in CAL patients and the likely response to home ventilatory support will be examined.Read moreRead less
Randomised Double-blind Controlled Trial Of Oxygen Versus Air To Palliate Intractable End-of-life Dyspnoea When Pa02 >55
Funder
National Health and Medical Research Council
Funding Amount
$463,318.00
Summary
Shortness of breath at the end-of-life is one of the most feared symptoms. Unlike most other symptoms, it worsens as death approaches. Despite the fact that more than 50,000 Australian will die an expected death in the next year, of whom the majority will have breathlessness toward the end-of-life, we know little about how best to treat this symptom. Oxygen is frequently introduced but we have not identified whether it is more effective than medical air, and, if it is more effective, which patie ....Shortness of breath at the end-of-life is one of the most feared symptoms. Unlike most other symptoms, it worsens as death approaches. Despite the fact that more than 50,000 Australian will die an expected death in the next year, of whom the majority will have breathlessness toward the end-of-life, we know little about how best to treat this symptom. Oxygen is frequently introduced but we have not identified whether it is more effective than medical air, and, if it is more effective, which patients would most benefit from it. Because of this lack of evidence, oxygen is only funded in Australia in community settings for people who have severely low oxygen levels in their blood. Palliative oxygen is provided on a compassionate basis at times but this is on an ad hoc basis and does not ensure equitable access for people at the end of life who experience shortness of breath. This multi-centre study will compare oxygen and air, with neither the participant nor caring clinicians knowing which treatment they will receive. After careful explanation, volunteers who agree to participate will be asked to use the oxygen machine for at least 15 hours each day for 7 days and fill out a diary twice each day. Five centres across Australia are planning to enroll 240 participants in this study. Outcomes will include whether the sensation of breathlessness has improved, the overall quality of life while being treated, the ability to perform activities of daily living and any side effects experienced. This study is eagerly awaited by clinicians and health planners not only in Australia but in North America and Europe. This study will provide data in a long-standing international debate about the role of oxygen in people with relatively normal levels of oxygen in their blood who suffer from shortness of breath at the end-of-life.Read moreRead less
Reduction Of Oxygen After Cardiac Arrest: The EXACT Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,891,021.00
Summary
We aim to conduct a Phase 3 multi-centre, randomised, controlled trial to determine whether reducing oxygen administration to target a normal level as soon as possible following successful resuscitation from out-of-hospital cardiac arrest, compared to current practice of maintaining 100% oxygen, improves patient survival at hospital discharge.
Low OxyGen Intervention For Cardiac Arrest Injury Limitation Trial (LOGICAL)
Funder
National Health and Medical Research Council
Funding Amount
$2,314,402.00
Summary
Life support with mechanical ventilation (MV) is required for most patients after cardiac arrest. Delivery of liberal oxygen therapy to patients receiving MV is standard care and exposes them to a high oxygen dose and higher blood oxygen levels. A higher amount of oxygen might be harmful after cardiac arrest, but the optimal oxygen therapy in these patients is uncertain. This study tests standard care versus a protective conservative dose of oxygen on neurological recovery after cardiac arrest.
The Role Of Oxygen Therapy As Second-line Treatment For Patients With Obstructive Sleep Apnoea Who Are Intolerant Of Continuous Positive Airway Pressure Therapy, And Characterising Ventilatory Loop Gain As A Predictor Of The Success Of Therapy.
Funder
National Health and Medical Research Council
Funding Amount
$87,198.00
Summary
Obstructive sleep apnoea (OSA) is an increasingly common condition in Australia. Continuous positive airway pressure (CPAP) therapy is the _gold-standard� in OSA treatment, but a majority of sufferers are unable to tolerate this for the period required to treat their condition. We will be conducting a large Australian multi-centre, randomised, placebo controlled trial to investigate the utility of nocturnal oxygen therapy alone, in those people with OSA who are unable to tolerate CPAP.
Nasal Highflow For Paediatric Acute Hypoxic Respiratory Failure
Funder
National Health and Medical Research Council
Funding Amount
$2,627,819.00
Summary
The burden of respiratory disease in children requiring intensive care admission is increasing despite better quality care in hospitals. This study investigates a new method, called nasal high flow, to support the breathing of children, that can be provided in regular children's wards in regional and metropolitan hospitals. The study anticipates to demonstrate that early intervention with nasal high flow reduces the need for intensive care admission.
TORPIDO2- Targeted Oxygen For Resuscitation Of Preterm Infants Effects On Developmental Outcomes 2
Funder
National Health and Medical Research Council
Funding Amount
$2,293,459.00
Summary
Either too much or too little oxygen (O2) causes prolonged harm and death, even if this imbalance is for a few minutes, as at birth. Nowhere is this balance more critical than in the care of the extremely preterm infant (below 28 weeks gestation) with lung immaturity (requiring O2) and antioxidant deficiency. The Torpido 2 study will randomize 1350 infants below 28 weeks gestation to determine long-term neurodevelopmental outcomes and survival after resuscitation with either 21% O2 (room air) or
Low oxygen levels during exercise occur in over half of all people with lung fibrosis and this is associated with poor outcomes. Low oxygen levels are sometimes treated by breathing extra oxygen during physical activity, but a lack of evidence has given rise to wide variations in practice and policy. This study will examine the benefits and costs of ambulatory oxygen therapy for people with lung fibrosis in a multi-site randomised controlled trial.